Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Jun 22:7:120-122.
doi: 10.1016/j.ajoc.2017.06.017. eCollection 2017 Sep.

Cicatricial ectropion in a patient treated with dupilumab

Alexander C Barnes  1 , Alexander D Blandford  1 , Julian D Perry  1
Affiliations
Case Reports

Cicatricial ectropion in a patient treated with dupilumab

Alexander C Barnes et al. Am J Ophthalmol Case Rep. .

Abstract

Purpose: To describe a case of bilateral conjunctivitis and cicatricial ectropion associated with dupilumab therapy for atopic dermatitis.

Observations: Severe hyperemia of the conjunctiva and eyelid margins, as well as cicatricial ectropion, began two months after starting weekly dupilumab injections for atopic dermatitis. The findings worsened over the next several months and improved after discontinuing dupilumab.

Conclusions and importance: Dupilumab is a promising intervention in the management of atopic dermatitis and asthma, however, little is known about its potential ocular adverse effects. We report the first case of dupilumab-associated ocular inflammation leading to cicatricial ectropion.

Keywords: Cicatricial ectropion; Conjunctivitis; Dupilumab; Ocular surface inflammation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
External photos showing bilateral conjunctival hyperemia, upper eyelid edema, and cicatricial ectropion (left greater than right). Additionally, there is left-sided blepharoptosis.
Fig. 2
Fig. 2
External photos showing bilateral resolution of conjunctivitis, eczematous reaction of lower eyelids and cheeks, and persistent cicatricial ectropion (left greater than right) following discontinuation of dupilumab and prednisone taper.
See this image and copyright information in PMC

References

    1. Thaçi D., Simpson E.L., Beck L.A. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387:40–52. - PubMed
    1. D'erme A.M. The beginning of biological treatment era in the atopic dermatitis management. Dermatol Ther. 2016;29:208–209. - PubMed
    1. Simpson E.L., Bieber T., Eckert L. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74:491–498. - PubMed
    1. Simpson E.L., Gadkari A., Worm M. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD) J Am Acad Dermatol. 2016;75(3):506–515. - PubMed
    1. Beck L.A., Thaçi D., Hamilton J.D. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–139. - PubMed

Publication types

LinkOut - more resources